CD274 and neoplasm: Among 262 patients treated with nivolumab monotherapy, across dose escalation (n = 48) and dose expansion cohorts (n = 214), [88] a 20% RR was observed irrespective of dose, HCV, or HBV infection status and PDL-1 expression on tumour cells.